Last reviewed · How we verify
Lorcaserin, 20 mg
Lorcaserin, 20 mg is a Small molecule drug developed by Midwest Biomedical Research Foundation. It is currently in Phase 1 development. Also known as: Belviq.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Lorcaserin, 20 mg |
|---|---|
| Also known as | Belviq |
| Sponsor | Midwest Biomedical Research Foundation |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome (PHASE3)
- Real-World Evidence on the Cardiovascular Safety of CONTRAVE® in the United States (U.S.)
- Treatment With Lorcaserin for Cocaine Use: The TLC Study (PHASE2)
- Study to Evaluate the Efficacy and Safety of Belviq XR® in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years (PHASE4)
- MEtformin and Lorcaserin for WeighT Loss in Schizophrenia (PHASE4)
- Drug Interaction and Self Administration Studies of Compounds for Cocaine Use Disorder (PHASE1)
- Phase I Functional Magnetic Resonance Imaging (fMRI) Pharmacodynamic Studies of Compounds for Opioid Use Disorder and Cocaine Use Disorder (PHASE1)
- Gene-by-Stress Interactions in Intervention Studies Significance (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lorcaserin, 20 mg CI brief — competitive landscape report
- Lorcaserin, 20 mg updates RSS · CI watch RSS
- Midwest Biomedical Research Foundation portfolio CI
Frequently asked questions about Lorcaserin, 20 mg
What is Lorcaserin, 20 mg?
Who makes Lorcaserin, 20 mg?
Is Lorcaserin, 20 mg also known as anything else?
What development phase is Lorcaserin, 20 mg in?
Related
- Manufacturer: Midwest Biomedical Research Foundation — full pipeline
- Also known as: Belviq
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing